Evidence map›Paper›PMID 42535261›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Exploring longitudinal relationships among Alzheimer's disease biomarkers.

Benjamin Saef, Kellen K Petersen, Katherine Volluz, Yan Li, Duygu Tosun, Marta Mila-Aloma, Leslie M Shaw, Henrik Zetterberg, Jeffrey L Dage, Carrie E Rubel and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Benjamin SaefDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Kellen K PetersenDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Katherine VolluzDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Yan LiDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Duygu TosunNorthern California Institute for Research and Education, San Francisco, California, USA.
Marta Mila-AlomaNorthern California Institute for Research and Education, San Francisco, California, USA.
Leslie M ShawDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Carrie E RubelBiogen, Cambridge, Massachusetts, USA.
Kyle FerberBiogen, Cambridge, Massachusetts, USA.
Lei Du-CunyAbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany.
Janaky CoomaraswamyTakeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.
Michael BarattaTakeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA.
Yulia MordashovaAbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany.
Ziad S SaadPrecision Measures, Johnson & Johnson, San Diego, California, USA.
Gallen Triana-BaltzerPrecision Measures, Johnson & Johnson, San Diego, California, USA.
Nicholas J AshtonInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Emily A MeyersAlzheimer's Association, Chicago, Illinois, USA.
Erin G RosenbaughThe Foundation for the National Institutes of Health, North Bethesda, Maryland, USA.
J Martin SabandalThe Foundation for the National Institutes of Health, North Bethesda, Maryland, USA.
Anthony W BannonAbbVie, North Chicago, Illinois, USA.
William Z PotterHighly qualified expert, Philadelphia, Pennsylvania, USA.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team
Suzanne E SchindlerDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.

Funding

Staging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3M
AbbVie Inc., Alzheimer's Association, Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation, Biogen, Janssen Research & Development, LLC, and Takeda Pharmaceutical Company LimitedFoundation for the National Institutes of HealthNIA NIH HHS R01 AG070941NIA NIH HHS R01AG070941 (S.E.S.)the Foundation for the National Institutes of Health (FNIH)
6 · The paper itself

Abstract

introductionWhile most studies of Alzheimer's disease (AD) examine cross-sectional relationships among biomarkers, longitudinal relationships are also highly relevant.

methodsThis study in the Alzheimer's Disease Neuroimaging Initiative cohort (n = 373) used non-parametric Spearman correlations to explore the relationships of baseline values and rates of change in plasma biomarkers and rates of change in key AD outcomes.

resultsCompared to rates of change of plasma biomarkers, baseline values of plasma biomarkers were more strongly associated with rates of change in key AD outcomes. Change in amyloid positron emission tomography (PET) was most strongly associated with baseline values of amyloid beta (Aβ)42/Aβ40 and phosphorylated tau (p-tau)217, especially in amyloid PET--negative individuals. Changes in cortical thickness and measures of cognition were most strongly associated with baseline p-tau217, especially in amyloid PET-positive individuals. DISCUSSION: Baseline p-tau217 is associated with rates of change of amyloid pathology and cognition. Visualization tools were developed to enable researchers to explore AD biomarker relationships.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkerstau ProteinsAgedBrainFemaleHumansLongitudinal StudiesMalePeptide FragmentsPositron-Emission TomographyAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseblood biomarkersdata visualizationneuroimagingplasma biomarkersR shiny app

Identifiers

PMID42535261
PMCPMC13425622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.